JP4146799B2 - ベンゾチアゾール誘導体 - Google Patents

ベンゾチアゾール誘導体 Download PDF

Info

Publication number
JP4146799B2
JP4146799B2 JP2003546888A JP2003546888A JP4146799B2 JP 4146799 B2 JP4146799 B2 JP 4146799B2 JP 2003546888 A JP2003546888 A JP 2003546888A JP 2003546888 A JP2003546888 A JP 2003546888A JP 4146799 B2 JP4146799 B2 JP 4146799B2
Authority
JP
Japan
Prior art keywords
methyl
methoxy
benzamide
benzothiazol
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003546888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518363A5 (https=
JP2005518363A (ja
Inventor
フロール，アレキサンダー
ヤーコップ−レートネ，ローランド
ノルクロス，ロジャー・ダヴィド
リーメル，クラウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005518363A publication Critical patent/JP2005518363A/ja
Publication of JP2005518363A5 publication Critical patent/JP2005518363A5/ja
Application granted granted Critical
Publication of JP4146799B2 publication Critical patent/JP4146799B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003546888A 2001-11-29 2002-11-21 ベンゾチアゾール誘導体 Expired - Fee Related JP4146799B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01128338 2001-11-29
PCT/EP2002/013046 WO2003045386A1 (en) 2001-11-29 2002-11-21 Benzothiazole derivatives

Publications (3)

Publication Number Publication Date
JP2005518363A JP2005518363A (ja) 2005-06-23
JP2005518363A5 JP2005518363A5 (https=) 2005-12-22
JP4146799B2 true JP4146799B2 (ja) 2008-09-10

Family

ID=8179392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546888A Expired - Fee Related JP4146799B2 (ja) 2001-11-29 2002-11-21 ベンゾチアゾール誘導体

Country Status (20)

Country Link
US (1) US6624163B2 (https=)
EP (1) EP1450797B1 (https=)
JP (1) JP4146799B2 (https=)
KR (1) KR100581704B1 (https=)
CN (1) CN1304383C (https=)
AR (1) AR037457A1 (https=)
AT (1) ATE330603T1 (https=)
AU (1) AU2002365506B2 (https=)
BR (1) BR0214488A (https=)
CA (1) CA2468311C (https=)
DE (1) DE60212694T2 (https=)
ES (1) ES2266608T3 (https=)
MX (1) MXPA04005077A (https=)
PA (1) PA8558701A1 (https=)
PE (1) PE20030821A1 (https=)
PL (1) PL373947A1 (https=)
RU (1) RU2301232C2 (https=)
TW (1) TW200408395A (https=)
UY (1) UY27559A1 (https=)
WO (1) WO2003045386A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2344132C2 (ru) * 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
RU2006112847A (ru) 2003-09-19 2007-11-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазолопиридина в качестве лигандов аденозинового рецептора
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
EP1677791A4 (en) 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
JP4740152B2 (ja) * 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
CN1989117B (zh) * 2004-07-22 2011-01-19 弗·哈夫曼-拉罗切有限公司 取代的苯并噻唑
JP5202946B2 (ja) * 2004-07-22 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
EA200700707A1 (ru) 2004-09-22 2007-08-31 Х. Лундбекк А/С Производные 2-ациламинотиазола
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374550D1 (en) 1982-12-21 1987-12-23 Johnsen Jorgensen Plastics Ltd Dispensing container
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
GB8717068D0 (en) * 1987-07-20 1987-08-26 Fujisawa Pharmaceutical Co Nitric ester derivative
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
DE69327572T2 (de) * 1992-05-21 2000-06-21 Otsuka Pharmaceutical Factory, Inc. Phosphonsäurediester-derivat
AU2001281817B2 (en) 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives

Also Published As

Publication number Publication date
KR20040062967A (ko) 2004-07-09
ES2266608T3 (es) 2007-03-01
US6624163B2 (en) 2003-09-23
MXPA04005077A (es) 2004-08-19
ATE330603T1 (de) 2006-07-15
WO2003045386A1 (en) 2003-06-05
DE60212694T2 (de) 2007-06-28
CA2468311C (en) 2011-03-15
RU2004119985A (ru) 2006-01-10
BR0214488A (pt) 2004-10-19
PL373947A1 (en) 2005-09-19
EP1450797A1 (en) 2004-09-01
EP1450797B1 (en) 2006-06-21
CN1596112A (zh) 2005-03-16
PE20030821A1 (es) 2003-10-04
KR100581704B1 (ko) 2006-05-22
AU2002365506B2 (en) 2006-08-10
RU2301232C2 (ru) 2007-06-20
CA2468311A1 (en) 2003-06-05
US20030134855A1 (en) 2003-07-17
JP2005518363A (ja) 2005-06-23
PA8558701A1 (es) 2003-09-05
UY27559A1 (es) 2003-05-30
CN1304383C (zh) 2007-03-14
AR037457A1 (es) 2004-11-10
TW200408395A (en) 2004-06-01
DE60212694D1 (de) 2006-08-03
AU2002365506A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
JP4216193B2 (ja) ベンゾチアゾール誘導体
RU2299203C2 (ru) 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора
JP4216192B2 (ja) アデノシン受容体リガンドとしてのベンゾチアゾール誘導体
JP4668265B2 (ja) ４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
JP4146799B2 (ja) ベンゾチアゾール誘導体
JP5202946B2 (ja) ベンゾチアゾール誘導体
EP1587799B1 (en) Benzoxazole derivatives and their use as adenosine receptor ligands
JP4408292B2 (ja) ベンゾチアゾール誘導体、およびアデノシンａ２ａレセプターに関連する疾患の処置におけるその使用
JP4426572B2 (ja) ベンゾチアゾール誘導体、およびアデノシンａ２ａ受容体に関連した疾患の処置でのその使用
KR100818028B1 (ko) 치환된 벤조티아졸
RU2299882C2 (ru) Бензотиофены в качестве модуляторов аденозинового рецептора
KR100834179B1 (ko) 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
HK1105199B (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080617

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080620

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110627

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees